As new data on COVID-19 emerges, the FDA has revised the authorizations for two monoclonal antibody treatments that are administered together: bamlanivimab and etesevimab. These may only be used when the patient is likely to have already been infected with or exposed to a variant that is susceptible to the aforementioned treatments. Monoclonal antibodies are lab made proteins. COVID-19 can mutate over time, which is why this update is necessary. These treatments do not count as a substitute for getting vaccinated. Data clearly shows that receiving the vaccine along with a booster shot is still the best way to lower the risk of contracting COVID-19 and experiencing the possible life threatening symptoms that come along with it.
To learn more, click here.